期刊文献+

紫杉醇纳米脂质体凝胶剂的制备及体外透皮研究 被引量:15

Preparation and in Vitro Transdermal Diffusion Characteristics of Paclitaxel Nano-liposomes Gels
原文传递
导出
摘要 目的制备紫杉醇纳米脂质体凝胶剂,考察其粒径、粒径分布、包封率、体外释放度及透皮特性。方法采用薄膜蒸发高压微射流法制备紫杉醇纳米脂质体,以卡波姆为凝胶基质,研制紫杉醇纳米脂质体凝胶剂,采用正交试验探索最佳工艺。用粒径测定仪测定脂质体的粒径及其粒径分布,低速-超速相结合法测定包封率,透析膜扩散法进行体外释放试验,以离体小鼠皮结合改良Franz扩散装置考察其体外透皮特性。结果紫杉醇纳米脂质体的最佳工艺:卵磷脂的含量为2%,药物与磷脂质量比为1∶30,磷脂与胆固醇的质量比为10∶1。测得的粒径为81.8 nm;粒径分布系数为0.180;平均包封率73.2%。纳米脂质体凝胶剂72 h累积释放百分率为79.04%;48 h的单位面积累积渗透量为429.68μg·cm?2。结论该制剂制备工艺简单,易于涂布,具有较高的包封率,粒径较小且分布均匀,体外释放缓慢。纳米脂质体能促进脂溶性药物紫杉醇透过皮肤。 OBJECTIVE To prepare the paclitaxel nano-liposomes gels, detect the particle size, particle diameter, the entrapment efficiency, the release and transdermal diffusion characteristics in vitro. METHODS Paclitaxel nano-liposomes were prepared using thin film evaporation high pressure microfluidization, added carbomer to prepare the paclitaxel nano-liposomes gels, and the optimal method was determined by the orthogonal test. The particle size, particle diameter of the modified liposomes was detected by nanoparticle size analyzer. The entrapment efficiency was determined by low-speed combination method with HPLC. The release study adopting membrane diffusion method. Using Franz diffusion cell and rats skin to investigate transdermal diffusion characteristics of the modified nano-liposomes gels in vitro. RESULTS The optimal formulation and preparing conditions were as the following: the content of lecithin was 2%, drug:lecithin=l : 30, lecithin : cholesterin=10:1. The particle size of the liposome prepared was 81.8 nm. The particle size distribution coefficient was 0.180. The average entrapment efficiency of the liposomes was up to 73.2%. The release amount of nano-liposomes gels was 79.04% at 72 h and the cumulative penetration amount per unit area was 429.68μg·cm^-2 at 48 h. CONCLUSION This preparation is prepared with simple technology and the entrapment efficiency of the paclitaxel is high. The particle sizes are small and uniform. Nano-liposomes gels feature a sustained release in vitro, the nano-liposomes can increase diffusion rate of paclitaxel through the skin of rats.
出处 《中国现代应用药学》 CAS CSCD 2015年第2期156-161,共6页 Chinese Journal of Modern Applied Pharmacy
基金 浙江省科技计划项目(2012C33033)
关键词 紫杉醇 纳米脂质体凝胶剂 正交试验 经皮渗透 paclitaxel nano-liposomes gels orthogonal design transdermal penetration
  • 相关文献

参考文献13

  • 1WANI M C, TAYLOR H L, WALL M E, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemie and antitumor agent from Taxus brevifolia [J]. J Am Chem Soc, 1971, 93(9): 2325-2327.
  • 2SUGIURA H, OMOTO M, HIROTA Y, et al. Density and fine structure of peripheral nerves in various skin lesions of atopic dermatitis [J]. Arch Dermatol Res, 1997, 289(3): 125-131.
  • 3原少斐,朱林佳,郑维锷,陈文俊.黄芩素联合紫杉醇对人肺癌细胞的生长抑制作用[J].中国现代应用药学,2013,30(12):1306-1310. 被引量:8
  • 4张珺,殷铁军.白蛋白结合型紫杉醇治疗晚期恶性肿瘤45例临床观察[J].中国医院药学杂志,2014,34(5):392-395. 被引量:10
  • 5PINCELLI C, FANT1NI F, MASSIMI P, et al. Neuropeptidesin skin from patients with atopic dermatitis: an immunohistochemical study [J]. Br J Dermatol, 1990, 122(6): 745-750.
  • 6TOYODA M, MOROHASHI M. Morphological assessment of the effects of cyclosporine A on mast cell-nerve relationship in atopic dermatitis [J]. Acta Derm Venererol, 1998, 78(5): 321-325.
  • 7刘辉,吴菡子,盛利.皮肤用脂质体的研究[J].药学进展,2000,24(3):141-144. 被引量:33
  • 8郭咸希.博莱霉素脂质体凝胶的制备和体外透皮性比较[J].中国药师,2009,12(12):1720-1722. 被引量:9
  • 9YANG T. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome [D]. Shenyang: Shenyang Pharmaceutical University, 2007.
  • 10ZHANG B. Study on paclitaxel liposome and its freeze-dried preparation [D]. Shenyang: Shenyang Pharmaceutical University, 2006.

二级参考文献32

  • 1梁秉文.透皮给药制剂[M].北京:中国医药工业出版社,1992,450-480.
  • 2曾抗 李国锋 等.鬼臼毒素脂质体软膏治疗尖锐湿疣的双盲随机对照试验[J].第一军医大学学报,1998,18(3):246-246.
  • 3陆彬.药物新剂型与新技术[M].北京:人民卫生出版社,2002.212.
  • 4Weiss RB,Donehower RC,Wiernik PH,et al. Hypersensi-tivity reactions from taxol[J],J Clin Oncol,1990,8(7):1263-1268.
  • 5Gelderblom H,Verweij J,Nooter K,et al.Cremophor EL:the drawbacks and advantages of vehicle selection for drug for-mulation[JH.EurJ Cancer,2001,37(13):1590-1598.
  • 6Green MR,Manikhas GM,OrlovS,et al.Abraxane,a novelCremophor-free,albumin-bound particle form of paclitaxel forthe treatment of advanced non-small-cell lung cancer [J].AnnOncol,2006,17(8):1263-1268.
  • 7Von Hoff DD,Ramanathan RK,Borad MJ,etal.Gemcitabineplus nab-paclitaxel is an active regimen in patients with ad-vanced pancreatic cancer:a phase I / E trial[J].J Clin Oncol,2011,29(34); 4548-4554.
  • 8Teneriello MG,Tseng PC,Crozier M,et al.Phase II evalua-tion of nanoparticle albumin-bound paclitaxel in platinum-sen-sitive patients with recurrent ovarian,peritoneal,or fallopiantube cancer[J].J Clin Oncol,2009,27(9):1426-1431.
  • 9Onetto N,Canetta R,Winograd B,et al.Overview of Taxolsafety[J].J Natl Cancer Inst monogr,1993,15:131-139.
  • 10ten Tije AJ,Verweij J,Loos WJ,etal.Pharmacological effectof formulation vehicles:implications for cancer chemotherapy[J].Clin Pharmacokinet,2003,42(7):665-685.

共引文献64

同被引文献123

引证文献15

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部